| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7c82e8b52d0bd4cc5f7920d414c5766
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72f8f81a35381d45a0e66e9efa216a0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c482b782564bcd8a22c3622856d46bc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38ed0d8e5aaaa5f6290475bf4991e208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_77ad045665d16313eb5f2f15939d2d6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ce8ad21796410ef7f31fc4a98b2d675 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-04 |
| filingDate |
2021-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_120066e92335b383bed45627cf3e015c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4565fc35990586e96b0a1f5e7b451ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a55c6279f40ca5d3a36f1741793e366c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_078e70890f86db9d1d53fc732070ec8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_739f0f76a477da041dccca1282663524 |
| publicationDate |
2021-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021236876-A2 |
| titleOfInvention |
Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| abstract |
Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadoI. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11597726-B2 |
| priorityDate |
2020-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |